coenzyme Q10 (CoQ10)

Ubiquinone ring with a chain of 10 isoprene units; redox equilibrium with ubiqunol serving in mitochondrial inner membrane to transfer electrons; presence during reconstitution of acetylcholine receptor into phospholipid vesicles yields vesicles active in catalyzing carbamylcholine-sensitive Na+ flux; RN refers to (all-E)-isomer; coenzyme Q10 depletion has been noted with use of statins

Also Known As:

Networked: 1163 relevant articles (152 outcomes, 311 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Littarru, Gian Paolo: 19 articles (10/2014 - 04/2003)
2.	Hirano, Michio: 17 articles (11/2014 - 01/2003)
3.	Niklowitz, Petra: 15 articles (07/2015 - 12/2002)
4.	Tiano, Luca: 15 articles (06/2015 - 01/2005)
5.	Beal, M Flint: 15 articles (05/2014 - 03/2002)
6.	Cordero, Mario D: 13 articles (03/2015 - 01/2010)
7.	Naini, Ali: 12 articles (08/2015 - 01/2003)
8.	Menke, Thomas: 12 articles (07/2015 - 12/2002)
9.	Littarru, G P: 12 articles (09/2014 - 04/2002)
10.	Quinzii, Catarina M: 11 articles (08/2015 - 07/2006)

Related Diseases

1.	Heart Failure 01/01/1985 - "Long-term coenzyme Q10 therapy: a major advance in the management of resistant myocardial failure." 02/01/2013 - "The benefit of coenzyme Q10 supplements in the management of chronic heart failure: a long tale of promise in the continued absence of clear evidence." 01/01/1985 - "Hence CoQ10 appears to be an effective therapeutic agent in advanced cases of heart failure. " 01/01/2003 - "Thus, based on the available controlled data CoQ10 is a promising, effective and safe approach in chronic heart failure. " 05/01/2003 - "Although a number of studies have reported clinical improvement in congestive heart failure patients after CoQ(10) supplementation to standard therapy, concerns about the design of these studies coupled to the small number of patients involved have limited their acceptance. "
2.	Neurodegenerative Diseases (Neurodegenerative Disease) 01/01/1999 - "These studies therefore raise the prospect that administration of CoQ10 may be useful for the treatment of neurodegenerative diseases." 07/21/1998 - "They provide further evidence that coenzyme Q10 can exert neuroprotective effects that might be useful in the treatment of neurodegenerative diseases." 01/01/2009 - "Phase III trials of high-dose CoQ10 in large sample sizes are needed to further ascertain the effects of CoQ10 in neurodegenerative diseases." 01/01/2009 - "Studies of in vitro models of neuronal toxicity and animal models of neurodegenerative disorders have demonstrated potential neuroprotective effects of CoQ10. " 06/01/2007 - "Based on its biochemical properties and the effects in animal models, several clinical trials evaluating CoQ10 have been undertaken in many neurodegenerative diseases. "
3.	Migraine Disorders (Migraine) 06/01/2011 - "Overall, results of the study demonstrate that children and adolescents with migraine improved over time with multidisciplinary, standardized treatment regardless of supplementation with CoQ10 or placebo. " 03/01/2002 - "Placebo-controlled trials are now necessary to determine the true efficacy of coenzyme Q10 in migraine prevention." 02/22/2005 - "Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial." 03/01/2002 - "The objective was to assess the efficacy of coenzyme Q10 as a preventive treatment for migraine headaches. " 06/01/2011 - "One-hundred-and-twenty children and adolescents with migraine headache were randomized in a crossover, double-blind, placebo-controlled, randomized, add-on study to receive a placebo or CoQ10 (100 mg) supplement for 224 days. "
4.	Cardiomyopathies (Cardiomyopathy) 02/01/1985 - "This biochemistry correlates with the effective treatment of cardiomyopathy with CoQ10." 01/01/1990 - "Coenzyme Q10 is safe and effective long-term therapy for chronic cardiomyopathy." 07/01/1988 - "Effective and safe therapy with coenzyme Q10 for cardiomyopathy." 10/15/2001 - "Is coenzyme Q10 helpful for patients with idiopathic cardiomyopathy?" 10/15/2001 - "Is coenzyme Q10 helpful for patients with idiopathic cardiomyopathy?"
5.	Parkinson Disease (Parkinson's Disease) 01/01/2007 - "For example, a 16-month randomized, placebo-controlled pilot trial in 80 subjects with mild Parkinson's disease found significant benefits for oral CoQ10 1,200 mg/day to slow functional deterioration. " 08/01/2015 - "Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson's disease." 07/10/2014 - "High-dose CoQ10 was well tolerated and improvements in the total Unified Parkinson's Disease Rating Scale (median, 37 vs. 27; p=0.048) were observed following study completion. " 01/01/2012 - "We included randomized controlled trials (RCTs) that compared coenzyme Q10 to placebo for patients who suffered early and midstage primary Parkinson's disease. " 01/01/2012 - "To assess the evidence from randomized controlled trials on the efficacy and safety of treatment with coenzyme Q10 compared to placebo in patients with early and midstage Parkinson's disease. "

Related Drugs and Biologics

1.	coenzyme Q10 (CoQ10)
2.	Antioxidants
3.	Vitamin E
4.	Ubiquinone
5.	Carnitine (L-Carnitine)
6.	Riboflavin (Vitamin B2)
7.	idebenone
8.	Magnesium
9.	Thioctic Acid (Lipoic Acid)
10.	ubiquinol

Related Therapies and Procedures

1.	Root Planing
2.	Oral Administration
3.	Cardiac Resynchronization Therapy
4.	Deep Hypothermia Induced Circulatory Arrest
5.	Defibrillators (Defibrillator)